Lipase inhibiting polymers

Details Lipase inhibiting polymers Lipase inhibiting polymers

1999-01-06

2002-03-05

Jones, Dameron L. (Department: 1616)

Drug, bio-affecting and body treating compositions

Solid synthetic organic polymer as designated organic active...

C514S909000

Reexamination Certificate

active

06352692

ABSTRACT:

BACKGROUND OF THE INVENTION
Human obesity is a recognized health problem with approximately ninety-seven million people considered clinically overweight in the United States. The accumulation or maintenance of body fat bears a direct relationship to caloric intake. Therefore, one of the most common methods for weight control to combat obesity is the use of relatively low-fat diets, that is, diets containing less fat than a “normal diet” or that amount usually consumed by the patient.
The presence of fats in a great many food sources greatly limits the food sources which can be used in a low fat diet. Additionally, fats contribute to the flavor, appearance and physical characteristics of many foodstuffs. As such, the acceptability of low-fat diets and the maintenance of such diets are difficult.
Various chemical approaches have been proposed for controlling obesity. Anorectic agents such as dextroamphetamine, the combination of the non-amphetamine drugs phentermine and fenfluramine (Phen-Fen), and dexfenflulamine (Redux) alone, are associated with serious side effects. Indigestible materials such as olestra (OLEAN®), mineral oil or neopentyl esters (see U.S. Pat. No. 2,962,419) have been proposed as substitutes for dietary fat. Garcinia acid and derivatives thereof have been described as treating obesity by interfering with fatty acid synthesis. Swellable crosslinked vinyl pyridine resins have been described as appetite suppressants via the mechanism of providing non-nutritive bulk, as in U.S. Pat. No. 2,923,662. Surgical techniques such as temporary ileal bypass surgery, are employed in extreme cases.
However, methods for treating obesity, such as those described above have serious shortcomings with controlled diet remaining the most prevalent technique for controlling obesity. As such, new methods for treating obesity are needed.
SUMMARY OF THE INVENTION
The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with or comprises One or more groups which can inhibit a lipase. Lipases are key enzymes in the digestive system which break down tri- and diglycerides, which are too large to be absorbed by the small intestine into fatty acids which can be absorbed. Therefore, inhibition of lipases results in a reduction in the absorption of fat. In one embodiment, the lipase inhibiting group can be a “suicide substrate” which inhibits the activity of the lipase by forming a covalent bond with the enzyme either at the active site or elsewhere. In another embodiment, the lipase inhibiting group is an isosteric inhibitor of the enzyme. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.


REFERENCES:
patent: 3780171 (1973-12-01), Irmscher et al.
patent: 3923972 (1975-12-01), Fields et al.
patent: 4160826 (1979-07-01), Fischetti
patent: 4211765 (1980-07-01), Johnson et al.
patent: 4218443 (1980-08-01), Comai et al.
patent: 4265879 (1981-05-01), Fields et al.
patent: 4302450 (1981-11-01), Comai et al.
patent: 4432968 (1984-02-01), Page et al.
patent: 4959179 (1990-09-01), Aronson et al.
patent: 5063210 (1991-11-01), Lange, III et al.
patent: 5089163 (1992-02-01), Aronson et al.
patent: 5137716 (1992-08-01), Weisenfeld
patent: 5200183 (1993-04-01), Tang et al.
patent: 5286481 (1994-02-01), Weisenfeld
patent: 5308766 (1994-05-01), Dennis et al.
patent: 5376640 (1994-12-01), Miyazaki et al.
patent: 5376674 (1994-12-01), Derungs et al.
patent: 5401498 (1995-03-01), Kesseler et al.
patent: 5427777 (1995-06-01), St. Pierre et al.
patent: 5427919 (1995-06-01), Dennis et al.
patent: 5453282 (1995-09-01), Kanauchi et al.
patent: 5453429 (1995-09-01), Bliem et al.
patent: 5474993 (1995-12-01), Rubin et al.
patent: 5484777 (1996-01-01), Lange, III et al.
patent: 5567597 (1996-10-01), Dennis et al.
patent: 5569452 (1996-10-01), Amidon et al.
patent: 5597810 (1997-01-01), Hoffman et al.
patent: 5607669 (1997-03-01), Mandeville, III et al.
patent: 5618530 (1997-04-01), Mandeville, III et al.
patent: 5624963 (1997-04-01), Mandeville, III et al.
patent: 5629338 (1997-05-01), Okuda et al.
patent: 5665348 (1997-09-01), Okayama et al.
patent: 5674482 (1997-10-01), Regan et al.
patent: 5679717 (1997-10-01), Mandeville, III et al.
patent: 5693675 (1997-12-01), Mandeville, III et al.
patent: 5703188 (1997-12-01), Mandeville, III et al.
patent: 5750524 (1998-05-01), Mera et al.
patent: 5942500 (1999-08-01), Perry
patent: 0 050 347 (1982-04-01), None
patent: 0 381 262 (1990-08-01), None
patent: WO 92/05788 (1992-04-01), None
Moreau, Hervé, et al., “Inactivation of Gastric and Pancreatic Lipases by Diethyl p-Nitrophenly Phosphate,” Biochemistry 30:1037-1041 (1991).
Gargouri, Y., et al., “Ajoene prevents fat digestion by human gastric lipase in vitro,” Biochimica et Biophysica Acta. 1006:137-139 (1989).
Gargouri, Y., et al., “Covalent inhibition of digestive lipases: an in vitro study,” Biochimica et Biophysica Acta. 1344:6-37 (1997).
Karamać, M. and Amarowicz, R., “Inhibition of Pancreatic Lipase by Phenolic Acids, Examination in vitro,” Verlag der Zeitschrift für Naturforschung:903-905 (1996).
Marguet, F., et al., “Digestive lipases: inactivation by phosphates,” Biochimica et Biophysica Acta. 1210:157-166 (1994).
Mannesse, M.L.M., et al., “Phosphonate analogues of triacylglycerols are potent inhibitors of lipase,” Biochimica et Biophysica Acta. 1259:56-64 (1995).
Martichonok, V. and Jones, J.B., “(Z)-Heptadec-8-enylboronic acid: a potential lipase inhibitor, ”J. Chem. Soc. Perkin Trans.I:2927-2929 (1995).
Vainio, P., et al., “Inhibition of Lipoprotein Lipase by Benzene Boronic Acid Effect of Apolipoprotein C-II,” Biochimica et Biophysica Acta. 711:386-390 (1982).
Bagree, A., et al., “Modification of &egr; -Amino Group of Lysine in Proteins by Acylation with Pryomellitic Dianhydride and &sgr;-Sulphobenzoic Anhydride,”FEBS Letters120(2):275-277 (1980).
Stadler, P., et al., “Inhibition of microbial lipases with steroismeric tridgylgycerol analog phosphonates,” Biochimica et Biophysica Actat. 1304:229-244 (1996).
Kawaguchi, K., et al., “Hesperidin as an Inhibitor of Lipases from Procine Pancreas andPseudomonas,”Biosci Biotech. Biochem.61(1):102-104 91997).
Bochenek, W.J. and Rodgers, J.B., “Effect of Polyol Detergents on Cholesterol and Triglyceride Absorption, ” Biochimica et Biophysica Acta 489-506 (1977).
Comai, K. and Sullivan, A.C., “Antiobesity activity of pluronic L-101, ”International Journal of Obesity4:33-42 (19800.
Han, L-K, et al., “Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet,”International Journal of Obesity23:174-179 (1999).

Affiliated with

Also associated with

Rating

Lipase inhibiting polymers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lipase inhibiting polymers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipase inhibiting polymers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2848581